Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Nivolumab + Regorafenib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 100||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent NSCLC without EGFR or ALK alterations, in combination with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov).|
|Regorafenib||Stivarga||BAY 73-4506||BRAF Inhibitor 21 CRAF Inhibitor 11 KIT Inhibitor 55 PDGFR Inhibitor (Pan) 28 RET Inhibitor 48 VEGFR Inhibitor (Pan) 34 VEGFR2 Inhibitor 36||Stivarga (regorafenib) is an inhibitor of several kinases including VEGFR, RET, KIT, PDGFR and RAF, thereby inhibiting tumor angiogenesis and tumor cell proliferation (PMID: 24756792). Stivarga (regorafenib) is FDA approved for colorectal cancer, hepatocellular carcinoma, and GIST (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04704154||Phase II||Nivolumab + Regorafenib||A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors||Active, not recruiting||USA | ITA | FRA | BEL||4|
|NCT04879368||Phase III||Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan||RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb)||Recruiting||USA | CAN||5|
|NCT04803877||Phase II||Nivolumab + Regorafenib||SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma||Recruiting||USA||0|
|NCT04126733||Phase II||Nivolumab + Regorafenib||Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)||Completed||USA||0|
|NCT03712943||Phase I||Nivolumab + Regorafenib||Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer||Active, not recruiting||USA||0|
|NCT04503694||Phase II||Nivolumab + Regorafenib||Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Intermediate-risk, Stage II-III Rectal Cancer (REGINA)||Recruiting||FRA | BEL||0|
|NCT04170556||Phase Ib/II||Nivolumab + Regorafenib||Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (GOING)||Active, not recruiting||ESP||0|